Literature DB >> 6318433

Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus.

J O Fleming, S A Stohlman, R C Harmon, M M Lai, J A Frelinger, L P Weiner.   

Abstract

Monoclonal antibodies were produced to JHMV-DL, a neurotropic member of the mouse hepatitis virus (MHV) or murine coronavirus group. Of 23 antibodies isolated, 10 were specific for the major envelope glycoprotein, gp180/90, 10 for the nucleocapsid protein, pp60, and 3 for the minor envelope glycoprotein, gp25. Eleven different MHV isolates were used in antibody binding assays to study antigenic relationships among the viruses. Each MHV isolate tested had a unique pattern of antibody binding, indicating that each is a distinct strain. Conservation of JHMV-DL antigenic determinants varied among the three proteins, with pp60 showing intermediate conservation, gp180/90 little conservation, and gp25 marked conservation in the different MHV strains. Monoclonal antibodies to pp60 proved most useful in delineating antigenic relationships among MHV strains. These antigenic groups correlated with pathogenic types, indicating that pp60 may be one of the gene products which mediates the distinct disease patterns manifested by different murine coronaviruses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6318433      PMCID: PMC7131482          DOI: 10.1016/0042-6822(83)90498-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Influenza virus recombination. I. Matrix protein markers and segregation during mixed infections.

Authors:  W G Laver; J C Downie
Journal:  Virology       Date:  1976-03       Impact factor: 3.616

3.  Tryptic peptide analysis of the structural proteins of vesicular stomatitis virus.

Authors:  T R Doel; F Brown
Journal:  J Gen Virol       Date:  1978-02       Impact factor: 3.891

4.  Pathogenesis of demyelination induced by a mouse hepatitis.

Authors:  L P Weiner
Journal:  Arch Neurol       Date:  1973-05

5.  Structural analysis of Rauscher virus Gp70 using monoclonal antibodies: sites of antigenicity and P15(E) linkage.

Authors:  H L Niman; J H Elder
Journal:  Virology       Date:  1982-11       Impact factor: 3.616

6.  Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans.

Authors:  B K Nottay; O M Kew; M H Hatch; J T Heyward; J F Obijeski
Journal:  Virology       Date:  1981-01-30       Impact factor: 3.616

7.  Comparative analysis of RNA genomes of mouse hepatitis viruses.

Authors:  M M Lai; S A Stohlman
Journal:  J Virol       Date:  1981-05       Impact factor: 5.103

8.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

9.  Structure of murine Ia antigens. Two dimensional electrophoretic analyses and high pressure liquid chromatography tryptic peptide maps of products of the I-A and I-E subregions and of an associated invariant polypeptide.

Authors:  M McMillan; J A Frelinger; P P Jones; D B Murphy; H O McDevitt; L Hood
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

10.  In vivo and in vitro models of demyelinating diseases. V. Comparison of the assembly of mouse hepatitis virus, strain JHM, in two murine cell lines.

Authors:  A Massalski; M Coulter-Mackie; R L Knobler; M J Buchmeier; S Dales
Journal:  Intervirology       Date:  1982       Impact factor: 1.763

View more
  94 in total

1.  Contributions of Fas-Fas ligand interactions to the pathogenesis of mouse hepatitis virus in the central nervous system.

Authors:  B Parra; M T Lin; S A Stohlman; C C Bergmann; R Atkinson; D R Hinton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Control of central nervous system viral persistence by neutralizing antibody.

Authors:  Chandran Ramakrishna; Cornelia C Bergmann; Roscoe Atkinson; Stephen A Stohlman
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Evolved variants of the membrane protein can partially replace the envelope protein in murine coronavirus assembly.

Authors:  Lili Kuo; Paul S Masters
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

4.  Membrane topology of coronavirus E protein.

Authors:  J Maeda; J F Repass; A Maeda; S Makino
Journal:  Virology       Date:  2001-03-15       Impact factor: 3.616

5.  Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Brief report.

Authors:  J Lecomte; V Cainelli-Gebara; G Mercier; S Mansour; P J Talbot; G Lussier; D Oth
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

6.  Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virus.

Authors:  K Yokomori; S C Baker; S A Stohlman; M M Lai
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry.

Authors:  Guann-Yi Yu; Michael M C Lai
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein.

Authors:  T M Gallagher; S E Parker; M J Buchmeier
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

9.  Role of the coronavirus E viroporin protein transmembrane domain in virus assembly.

Authors:  Ye Ye; Brenda G Hogue
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

10.  Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virus.

Authors:  S E Parker; T M Gallagher; M J Buchmeier
Journal:  Virology       Date:  1989-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.